Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, double-blind study

Clinical Nephrology

Volumn 77, Issue 1, 2012, Pages 8-17

  Haag Weber, Marianne ^a   Eckardt, Kai Uwe ^b   Hörl, Walter H ^c   Roger, Simon D ^d   Vetter, Andrea ^e   Roth, Karsten ^f  

^a Kuratorium für Dialyse und Nierentransplantation e V   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d GOSFORD HOSPITAL   (Australia)

^e Sandoz Biopharmaceuticals   (Germany)

^f Sandoz Pharma Ltd   (Switzerland)

Author keywords

Anemia; Chronic kidney disease; HX575; Predialysis; Subcutaneous

Indexed keywords

ERYTHROPOIETIN ANTIBODY; NEUTRALIZING ANTIBODY; PREDNISONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; IMMUNOGENICITY; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSTATE CARCINOMA; PRURITUS; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84855436897     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107304     Document Type: Article

References (30)

1. th March 2011).
2. Seidl A, Hainzl O, Richter M, Fischer R, Boehm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London G, Macdougall IC. Tungsten-mediated unfolding and aggregation of epoetin alfa in prefilled syringes as root cause for the occurrence of neutralising antibodies in an investigational clinical trial of subcutaneous administration. Pharm Res. 2011; DOI: 10.1007/S11095-011-0621-4
3. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol. 2004; 15: 398-406.
4. Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pure red cell aplasia induced by erythropoiesisstimulating agents. Clin J Am Soc Nephrol. 2008; 3: 193-199.
5. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002; 346: 469-475.
6. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009; 361: 1848-1855. (Supplementary Appendix available from: http://www.nejm.org/doi/suppl/10.1056/NE J Moa074037/suppl_file/nejm_ma cdougall_1848sa1. pdf; accessed 7th March 2011).
7. Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011; 126: 114-118.
8. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008; 74: 1617-1622.
9. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK: European Medicines Agency, 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf (accessed 8 August 2011).
10. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, UK: European Medicines Agency, 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf (accessed 8th August 2011).
11. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, UK: European Medicines Agency, 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf (accessed 8 August 2011).
12. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). London, UK: European Medicines Agency, 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf (accessed 8 August 2011).
13. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011; 80: 88-92.
14. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004; 3: 43-47.
15. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005; 25: 954-962.
16. Brockmeyer C, Seidl A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice. 2009; 15: 34-40.
17. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003; 18: 1257-1259.
18. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004; 351: 1403-1408.
19. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002; 1: 457-462.
20. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004; 251 (Suppl 2): II4-II9.
21. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006; 21 (Suppl 5): v9-v12.
22. Jiang Y, Nashed-Samuel Y, Li C, Liu W, Pollastrini J, Mallard D, Wen ZQ, Fujimori K, Pallitto M, Donahue L, Chu G, Torraca G, Vance A, Mire-Sluis T, Freund E, Davis J, Narhi L. Tungsten-induced protein aggregation: solution behavior. J Pharm Sci. 2009; 98: 4695-4710.
23. Bee JS, Nelson SA, Freund E, Carpenter JF, Randolph TW. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci. 2009; 98: 3290-3301.
24. Liu W, Swift R, Torraca G, Nashed-Samuel Y, Wen ZQ, Jiang Y, Vance A, Mire-Sluis A, Freund E, Davis J, Narhi L. Root cause analysis of tungsteninduced protein aggregation in prefilled syringes. PDA J Pharm Sci Technol. 2010; 64: 11-19.
25. Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-Study Group. Therapeutic equivalence, longterm efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009; 72: 380-390.
26. Roth K, Locatelli F, Hörl WH. Prospective, multicentre study of HX575 (human recombinant epoetin alfa) treatment in patients with chronic kidney disease (CKD) applying a target haemoglobin of 10-12 g/dl. J Am Soc Nephrol. 2010; 21: 432A-433A.
27. Dellanna F, Hartmann U, Turner M. HX575 epoetin-alfa effectively maintains stable haemoglobin levels in patients on haemodialysis with symptomatic anemia due to chronic renal failure. BANTAO Journal. 2009; 7 (Suppl 1): 32.
28. Piepenstock M, Langenbahn H. Biosimilar epoetin alfa as part of an integrated anemia management in patients with chronic renal failure. Abstract and poster presented at the World Congress of Nephrology 2009.
29. London G, Gesualdo L, Turner M, Lee C, Mac-Donald K, Muenzberg M, Abraham I. Background, objectives and methodology of the MONITOR-CKD5 study - a pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of treatment with biosimilar epoetin alfa in patients receiving hemodialysis. NDT Plus. 2010; 3: iii26-iii274.
30. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther. 2010; 10: 1011-1018.